Inactive Instrument

ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Biotechnology & Medical Research

Immunogen, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

July 30, 2021 at 06:37 am EDT

ImmunoGen, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 16.948 million compared to USD 15.025 million a year ago. Operating loss was USD 27.369 million compared to USD 18.362 million a year ago. Net loss was USD 30.741 million compared to USD 24.298 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.14 a year ago. For the half year, total revenue was USD 32.654 million compared to USD 28.312 million a year ago. Operating loss was USD 56.285 million compared to USD 42.172 million a year ago. Net loss was USD 64.792 million compared to USD 53.386 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.31 a year ago.

Latest news about ImmunoGen, Inc.

AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	Feb. 13	MT
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	Feb. 12	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	Feb. 12	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	Feb. 12	CI
Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	Feb. 12	MT
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12	MT
AbbVie Acquires ImmunoGen for $31.26 per Share	Feb. 12	MT
AbbVie: acquisition of ImmunoGen finalized	Feb. 12	CF
Immunogen, Inc. Announces Board Changes	Feb. 12	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	Feb. 11	CI
AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	Feb. 11	CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Biotechnology Index	Feb. 08	CI
ImmunoGen Insider Sold Shares Worth $352,391, According to a Recent SEC Filing	Feb. 07	MT
ImmunoGen Insider Sold Shares Worth $588,733, According to a Recent SEC Filing	Feb. 07	MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks	Feb. 02	DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
Immunogen Insider Sold Shares Worth $5,562,450, According to a Recent SEC Filing	Jan. 19	MT
Drugmakers kick off industry conference with two cancer deals	Jan. 08	RE
J&J to buy cancer therapy developer Ambrx for $2 bln	Jan. 08	RE
2023 highlights of the stock market year	Dec. 21
BioMarin settles with Elliott, adds 3 independent directors	Dec. 20	RE
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	Dec. 10	CI
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup	Dec. 08	DJ

Chart ImmunoGen, Inc.

Duration

Period

More charts

Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+48.15%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research